ICD-10-CM 2027 diagnosis code
T36.AX5AAdverse effect of fluoroquinolone antibiotics, initial encounter
T36.AX5A is a valid, billable ICD-10-CM code for adverse effect of fluoroquinolone antibiotics, initial encounter. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Adverse effect of fluoroquinolone antibiotics, init
Code last changed in FY2026 (effective October 1, 2025). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About T36.AX5A
T36.AX5A is the ICD-10-CM diagnosis code for adverse effect of fluoroquinolone antibiotics, initial encounter. It belongs to category T36 (poisoning by, adverse effect of and underdosing of systemic antibiotics), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
The 7th character "A" means initial encounter: use it while the patient is receiving active treatment for the condition.
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 791 (Prematurity with Major Problems, relative weight 4.1075), DRG 793 (Full Term Neonate with Major Problems, relative weight 4.2195), DRG 917 (Poisoning and Toxic Effects of Drugs with MCC, relative weight 1.57) and DRG 918 (Poisoning and Toxic Effects of Drugs without MCC, relative weight 0.872), in MDC 15 (Newborns and Other Neonates with Conditions Originating in the Perinatal Period) and MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.
It was added in FY2026, effective October 1, 2025.
7th character
Ainitial encounter
Other encounter types for T36.AX5:
Notes that apply from higher levels
Instructions written at a parent level also apply to T36.AX5A.
Broader instructions also apply from T36-T50 Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances and Chapter 19: Injury, poisoning and certain other consequences of external causes.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 15 · Newborns and Other Neonates with Conditions Originating in the Perinatal Period
MDC 15 · Newborns and Other Neonates with Conditions Originating in the Perinatal Period
MDC 21 · Injuries, Poisonings and Toxic Effects of Drugs
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2026 (effective 10/1/2025): Added
- No changes since FY2026.
Common questions about T36.AX5A
Is T36.AX5A billable?
- Yes. T36.AX5A is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
What does the "A" at the end of T36.AX5A mean?
- It is the 7th character for initial encounter. Per the official guidelines, use it while the patient is receiving active treatment for the condition.
Can T36.AX5A be used as a principal diagnosis?
- No. It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.
Is T36.AX5A a CC or MCC?
- No. T36.AX5A is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does T36.AX5A group to?
- T36.AX5A is used in the MS-DRG v44.0 logic for MS-DRG 791 (Prematurity with Major Problems), MS-DRG 793 (Full Term Neonate with Major Problems), MS-DRG 917 (Poisoning and Toxic Effects of Drugs with MCC) and MS-DRG 918 (Poisoning and Toxic Effects of Drugs without MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.